Abstract:BackgroundSince China has a unique system of delivering HIV care that includes all patients' records. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART are understudied in the China despite subsequent virological suppression (viral load < 50 copies/mL) is unknown.MethodsThe authors conducted a retrospective cohort study using data from the national HIV treatment sub-database of Zhejiang province to identify records of HIV+ patients. Patient records were included if they were < 16 years of age, had an initial CD4 count < 100 cells/mu L, were on continuous HAART for at least one year by the end of December 31, 2014; and achieved and maintained continued maximum virological suppression (MVS) (< 50 copies/ml) by 9 months after starting HAART. The primary endpoint for analysis was time to first CD4+ T cell count recovery (>= 200, 350, 500 cells/mu L). Cox proportional hazard regression was used to identify the risk factors for CD4+ T cell count recovery to key thresholds (200350, 350-500, >= 00 cells/mu L) by the time of last clinical follow-up (whichever occurred first), key thresholds (follow-up date for analysis), with patients still unable to reach the end-points being censored by the end December 31, 2014 (follow-up date for analysis).ResultsOf the 918 patients who were included in the study, and the median CD4+ T cell count was 39 cells/mu L at the baseline. At the end of follow-up, 727 (79.2%), 363 (39.5%) and 149 (16.2%) patients had return to >= 200, 350, and 500 cells/mu L, respectively. Kaplan-Meier analysis demonstrated that the rate of patients with CD4+ count recovery to >= 200, 350, and 500 cells/mu L after 1 year on HAART was 43.6, 8.6, and 2.5%, respectively, after 3 years on treatment was 90.8, 46.3, and 17.9%, respectively, and after 5 years on HAART was 97.1, 72.2, and 36.4%, respectively. The median time to return to 200-350, 350-500, >= 500cells/mu L was 1.11, 3.33 and 6.91 years, respectively. Factors of age (aHR = 0.77, 95% CI 0.61-0.97), baseline CD4+ count (aHR = 1.60, 95% CI 1.37-1.86), initial regimens, changes in regimen (aHR = 0.58, 95% CI 0.49-0.69), and inclusion of a cotrimoxazole prophylaxis (aHR = 0.66, 95% CI 0.51-0.85) were associated with CD4+ T cell count recovery.ConclusionThe proportion of patients with initially low CD4 counts after nine months of treatment and that achieved continuous virological suppression was greater than 70% for persons with CD4+ count >= 350. Conversely, only 35% of patients recovered to levels of 500 cells/mu L after 5 years of treatment, and levels continued to rise significantly with further long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy

Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis

The Factors Related To Cd4+T-Cell Recovery And Viral Suppression In Patients Who Have Low Cd4+T Cell Counts At The Initiation Of Haart: A Retrospective Study Of The National Hiv Treatment Sub-Database Of Zhejiang Province, China, 2014

A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries

Risk Factors and Clinical Prediction Models for Low-Level Viremia in People Living with HIV Receiving Antiretroviral Therapy: an 11-Year Retrospective Study

Determinants of Virological Failure after 1 Year's Antiretroviral Therapy in Vietnamese People with HIV: Findings from a Retrospective Cohort of 13 Outpatient Clinics in Six Provinces.

Assessment of the magnitude and associated factors of immunological failure among adult and adolescent HIV-infected patients in St. Luke and Tulubolo Hospital, Oromia Region, Ethiopia

Clinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care

The Predictive Role of CD4+ Cell Count and CD4/CD8 Ratio in Immune Reconstitution Outcome among HIV/AIDS Patients Receiving Antiretroviral Therapy: an Eight-Year Observation in China.

Biological parameters determining the effectiveness of monitoring of HIV / AIDS infected patients in Morocco

Accuracy of quantitative HIV‐1 RNA test methods at 1000 copies/mL and the potential impact of differences in assay calibration on therapy monitoring of patients

Association between CD4 lymphocyte count and the incidence of comorbidities in Human immunodeficiency virus positive patients with virological suppression after antiretroviral treatment

Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China

Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection

Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy

Determinants of CD4+ T Cell Recovery During Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV-1 DNA.

Virological failure and associated factors among patients receiving anti-retroviral therapy in Ethiopia: A systematic review and meta-analysis

Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy

Success and failure of initial antiretroviral therapy in adults: an updated systematic review of 77,999 subjects from 1994 to 2017.